Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis

Patent metadata

Field	Value
Publication number	US-10082496-B2
Application number	US-201615201667-A
Country	US
Kind code	B2
Filing date	Jul 5, 2016
Priority date	Sep 10, 2014
Publication date	Sep 25, 2018
Grant date	Sep 25, 2018

Abstract

The described invention provides methods for targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.

First claim

What is claimed is:

1. A method for targeting emopamil binding protein for treating a subject with colorectal cancer with a pharmaceutical composition comprising an Emopamil binding protein (EBP)-modulating anti-cancer compound, wherein the EBP-modulating anti-cancer compound is

or a functional equivalent selected from the group consisting of:

the method comprising
(a) isolating a colorectal tumor sample comprising a population of cancer cells from the subject;
(b) providing (i) an aliquot of the colorectal tumor sample in (a) as a test population of cancer cells, (ii) a known population of cancer cells sensitive to the EBP-modulating anticancer compound (positive control), and (iii) a known population of cancer cells insensitive to the EBP-modulating anticancer compound (negative control),
wherein the known population of cancer cells sensitive to the EBP modulating anti-cancer compound (positive control) is a population of cancer cells selected from the group consisting of DLD1 cells, HT29 cells, SW620 cells, SE480 cells, Caco-2 cells, Lovo cells, and HC116 p53-/-A1309 cells, and
the known population of cancer cells insensitive to the EBP-modulating anticancer compound (negative control) is a population of cancer cells selected from the group consisting of HCT116 cells and RKO cells;
(c) determining whether the aliquot of the colorectal tumor sample contains a subpopulation of cancer cells sensitive to the composition comprising the EBP-modulating anti-cancer compound by
(1) contacting the EBP-modulating anticancer compound to the populations of cancer cells in (b);
(2) measuring EBP enzyme activity and cholesterol synthesis rate for each population of cancer cells,
wherein
in a cancer cell sensitive to the EBP modulating anti-cancer compound, an amount of the EBP-modulating anti-cancer compound is effective to decrease EBP enzyme activity and to decrease the rate of endogenous cholesterol synthesis, while
in a cancer cell insensitive to the EBP modulating anti-cancer compound, an amount of the EBP-modulating anti-cancer compound is effective to increase EBP activity and to increase the rate of endogenous cholesterol synthesis;
and
(d) upon determining that the test population of colorectal cancer cells contains a population of cancer cells sensitive to the EBP modulating anti-cancer compound in (c), treating the colorectal tumor by administering to the subject the pharmaceutical composition containing a therapeutic amount of the EBP modulating anti-cancer compound.

2. The method according to claim 1 , wherein in the cancer cell sensitive to the EBP modulating anti-cancer compound, the effective amount of the EBP-modulating anti-cancer compound is effective to cause accumulation of a Δ8 sterol intermediate.

3. The method according to claim 2 , wherein the Δ8 sterol intermediate is 5α-cholest-8-(9)-en-3β-ol (Δ8 -cholesetenol).

4. The method according to claim 1 , wherein in the cancer cell sensitive to the EBP-modulating anticancer compound, the effective amount of the EBP modulating anti-cancer compound is effective to cause downregulation of SREBP-2.

5. The method according to claim 1 , wherein in the cancer cell sensitive to the EBP-modulating anticancer compound, the effective amount of the EBP modulating anti-cancer compound is effective to cause downregulation of SREBP-2 genes.

6. The method according to claim 1 , wherein in the cancer cell sensitive to the EBP-modulating anticancer compound, the effective amount of the EBP modulating anti-cancer compound is effective to cause downregulation of SREBP-2 and one or more SREBP-2 target genes of the cholesterol biosynthetic pathway selected from the group consisting of ACAT2; MHGCS1; HMGCR; MVK; PMVK; MVD; ID11/ID12; FDFS;
GGPS1; FDFT1; SQLE; LSS; CYPS1A1; TM75F2; SCAMOL; NSDHL; HSD17B7;
EBP; SC5D; DHCR7; and DHCR24.

7. The method according to claim 1 , wherein the cancer cell sensitive to the EBP-modulating anti-cancer compound comprises a truncated APC protein.

8. The method according to claim 1 , wherein the therapeutic amount of the EBP-modulating anti-cancer compound is effective to reduce proliferation of the cancer cell sensitive to the EBP modulating anti-cancer compound, to reduce invasiveness of the cancer cell sensitive to the EBP modulating anti-cancer compound, increase apoptosis of the cancer cell sensitive to the EBP modulating anti-cancer compound, reduce growth of a tumor comprising the cancer cell sensitive to the EBP modulating anti-cancer compound, reduce tumor burden, improve progression free survival, improve overall survival, achieve remission of disease, or a combination thereof.

9. The method according to claim 1 , wherein the pharmaceutical composition comprising a first amount of the EBP-modulating anticancer compound further comprises a second amount of a compound selected from the group consisting of dendrogenin A, SR31747A, tamoxifen, emopamil, verapamil, cis-flupentixol, trifluoroperazine, 7-ketocholestenol, haloperidol, and fenpropimorph.

10. A method for identifying a therapeutic EBP-modulating anticancer compound for targeting emopamil binding protein for treating a subject with colorectal cancer comprising
(a) dividing a population of cancer cells sensitive to a known EBP-modulating anti-cancer compound into aliquoted samples of the population of cancer cells,
wherein
the population of cancer cells sensitive to the known EBP-modulating anti-cancer compound is a population of DLD 1 cells or HT29 cells,
the known EBP-modulating anti-cancer compound is

(b) contacting one sample of the population of sensitive cancer cells with a candidate EBP-modulating anti-cancer compound, contacting a second sample of the sensitive population of cancer cells with the known EBP-modulating anticancer compound (positive control), and contacting a third sample of the sensitive population of cancer cells with a compound that does not modulate EBP activity (negative control);
(c) measuring EBP enzyme activity and cholesterol synthesis rate for the candidate EBP-modulating compound, the positive control and the negative control in (b),
wherein
an amount of the known EBP-modulating anti-cancer compound is effective to decrease EBP activity and to decrease the rate of endogenous cholesterol synthesis in a sensitive cancer cell;
(d) ranking a plu

Assignees

• Univ Texas

Inventors

• De Brabander Jef
• Shay Jerry W
• Wang Wentian
• Nijhawan Deepak
• Theodoropoulos Pano

Classifications

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K31/454

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D211/96

  Sulfur atom · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title